Related Experiment Videos
Are we ready for pharmacogenomics in heart failure?
1Service de Cardiologie, et Association Claude Bernard-Université Paris VI, Hôpital Pitié-Salpêtrière, 47-83, Boulevard de l'Hôpital, 75013, Paris, France.
European Journal of Pharmacology
|April 13, 2001
Summary
Genetic factors significantly influence heart failure development and progression. Identifying these genetic markers is crucial for personalized pharmacogenetics in heart failure treatment.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Heart failure presents high mortality and morbidity.
- Genetic background plays a significant role in heart failure onset and progression.
- Familial dilated cardiomyopathy is genetically heterogeneous with identified genes and loci.
Purpose of the Study:
- To explore the role of genetic factors in heart failure.
- To investigate genetic underpinnings of dilated cardiomyopathy.
- To assess the potential of pharmacogenetics in tailoring heart failure therapies.
Main Methods:
- Review of identified genes and loci associated with familial dilated cardiomyopathy.
- Analysis of hypotheses regarding cytoskeletal and sarcomeric protein defects.
- Examination of genetic polymorphisms influencing drug response in non-monogenic heart failure.
Main Results:
- Mutations in genes like dystrophin and lamin A/C are linked to dilated cardiomyopathy.
- Defects in cytoskeletal or sarcomeric proteins are implicated in heart failure pathogenesis.
- Genetic polymorphisms, such as ACE gene I/D, may predict response to treatments like ACE inhibitors.
Conclusions:
- Genetic heterogeneity is a key feature of dilated cardiomyopathy.
- Understanding genetic factors is vital for developing personalized heart failure treatments.
- Pharmacogenetics holds promise for optimizing polypharmacy in heart failure management.